Skip to Content
Merck
CN

M6014

Met-Leu-Phe acetate salt

≥97% (HPLC)

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C20H31N3O4S
CAS Number:
Molecular Weight:
409.54
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥97% (HPLC)

storage temp.

−20°C

SMILES string

CSCCC(N)C(=O)NC(CC(C)C)C(=O)NC(Cc1ccccc1)C(O)=O

InChI

1S/C20H31N3O4S/c1-13(2)11-16(22-18(24)15(21)9-10-28-3)19(25)23-17(20(26)27)12-14-7-5-4-6-8-14/h4-8,13,15-17H,9-12,21H2,1-3H3,(H,22,24)(H,23,25)(H,26,27)

InChI key

CHDYFPCQVUOJEB-UHFFFAOYSA-N

Analysis Note

Exhibits very weak chemotactic properties.


Storage Class

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Didier G Ebo et al.
Journal of immunological methods, 375(1-2), 30-38 (2011-09-29)
Stimulated human basophils exhibit different degranulation patterns with release of mediators and appearance of activation markers such as CD63 and CD203c. Traditionally, released mediators are quantified in the supernatant of activated cells, whereas the expression of activation markers by individual
S Pontremoli et al.
The Journal of biological chemistry, 265(2), 706-712 (1990-01-15)
Two major protein kinase C (PKC) isozymes, accounting for approximately 95% of the total activity in human neutrophils, were separated by hydroxyapatite chromatography and were identified as beta-PKC (60% of the total) and alpha-PKC (35% of the total). No gamma-PKC
E S Buescher et al.
Cancer immunology, immunotherapy : CII, 37(1), 26-30 (1993-07-01)
During a phase I trial of interleukin-1 alpha (IL-1 alpha) in patients with ovarian carcinomas, the effects of this treatment on blood granulocyte respiratory burst and locomotive responses were examined. Differences in baseline granulocyte function in patients as well as